All four of the cutaneous UPS (a.k.a. pleomorphic dermal sarcomas) in our cohort experienced clinical benefit from anti-PD1 therapy, as opposed to only 2 of 15 (13%) UPS tumors from other primary locations. Here, PDCD1 is linked to undifferentiated pleomorphic sarcoma.